Programs

The National Cancer Institute’s (NCI) Clinical Proteomic Technologies for Cancer (CPTC) initiative is composed of three major, integrated programs, all working in tandem to translate protein biomarker discoveries into clinical utility: the Clinical Proteomic Technology Assessment for Cancer (CPTAC) program, the Advanced Platforms and Computational Sciences program, and the Proteomic Reagents and Resources Core. Collaboration is an integral part of the CPTC initiative, and CPTC also encourages industry partnerships through the NCI’s Small Business Innovation Research (SBIR) & Small Business Technology Transfer (STTR) Programs.

Click on the different sections of the graphic below to learn more about the specific components of CPTC.

Click here for a screen reader-friendly version of this graphic.

CPTAC Centers

The goal of the team-based CPTAC network is to optimize key protein technologies at every step of the biomarker discovery and verification pipelines and make these resources available to the public. This enables comparison of information among laboratories – and significantly improves the quality of biomarker candidates that enter clinical trials as diagnostic tests. There are currently five teams in the CPTAC network, focusing on mass spectrometry and protein microarrays.

Click Here to Learn More

Clinical Proteomic Reagents and Resources Core

The Clinical Proteomic Reagents and Resources Core serves as a central resource for the scientific community. This program provides researchers with protein mixtures, capture reagents, standard operating procedures, and other resources needed for protein analysis.

Click Here to Learn More

Advanced Proteomic and Computational Sciences

The goal of the Advanced Platforms and Computational Sciences project is to develop next generation tools, technologies, and information resources for protein research. These tools allow scientists to better understand the difference between proteins from healthy cells versus cancer cells, enabling the development of new ways to detect and treat cancer early.

Click Here to Learn More

SBIR

The NCI's Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are NCI's engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. Through a variety of funding opportunities, the SBIR & STTR foster research and development for anticancer agents, biomarkers, informatics, medical devices, nanotechnology, proteomics, pharmacodynamics, and many programs designed to prevent, diagnose, and treat cancer.

Click Here to Learn More

Community Resources

All resources developed through CPTC are made available to the community through the Reagents Data Portal.

Click here to launch the Reagents Data Portal.